- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05164263
Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in T2DM Patients - EASE Study (EASE)
Real World Safety & Efficacy Experience of Empagliflozin With or Without Metformin in Patients With Type II Diabetes Mellitus
Study Objective To evaluate the safety and tolerability of Empagliflozin with or without metformin in patients with Type II Diabetes Mellitus in the Pakistani population.
Study design Open-label, prospective, observational, single arm, multi-center, post-marketing surveillance study.
Sample size The estimated sample size will be n=156. Duration of study 12 months (data lock point will be completion of 6 months' follow-up from the time of last patient's enrollment date) Safety Assessment: Patient will be monitored for Hypoglycemia, Dehydration, Hypotension, Urinary Tract Infections, Fungal Infections, Nausea, Vomiting, Diarrhea, Abdominal Discomfort, Flatulence, Asthenia, Indigestion and Other side effects (if any).
Follow up visits: After recruitment, patient is supposed to have three visits for follow-ups.
Visit 1: 4 to 6 weeks of initiation of therapy. Visit 02: At 12 weeks of initiation of therapy. Visit 03: At 24 weeks of initiation of therapy.
LABORATORY TESTING:
Reputable Lab is considered for laboratory testing of diabetes patients i.e. HbA1C%, FBG, RFT and urine R/E. The certified clinical lab will be responsible for receiving and analyzing clinical sample. Patients will have special discount of upto 50% for study related laboratory investigations.
Where in Urine Routine Examination (Urine R/E), we consider as follows:
Visual Examination:
- Urine color: Normal (Yellow), Pale Yellow, Dark Yellow, Brown, Red or Pink or any other.
- Urine clarity: Clear, slightly Cloudy, cloudy or turbidity
Chemical Examination:
- Specific gravity
- pH
- Bilirubin
- Urobilinogen
- Protein
- Ketone
- Leukocyte Esterase
Microscopic Examination:
- Red Blood Cells:
- Epithelial Cells:
- Amorphous:
- Pus Cells
- Bacteria
- Yeast
- Casts
- Crystals
Where in Renal Function Test (RFT), we consider as follows:
- Blood Urea Nitrogen (BUN): mg/dL
- Serum Creatinine: mg/dL
- Estimated Glomerular Filtration Rate (eGFR): mL/min/1.73 m2
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Syed Hussain Abidi
- Phone Number: +923322583236
- Email: mdr.hussainabidi@gmail.com
Study Contact Backup
- Name: Umar Wahab
- Phone Number: +923339158285
- Email: dromarwahab@yahoo.com
Study Locations
-
-
-
Islamabad, Pakistan
- Recruiting
- Umar Diabetes Foundation
-
Contact:
- Umar Wahab
- Phone Number: +923339158285
- Email: dromarwahab@yahoo.com
-
-
-
-
-
Colombo, Sri Lanka
- Active, not recruiting
- NHSL
-
Kandy, Sri Lanka
- Recruiting
- NHK
-
Contact:
- Charles Antonypillae
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Patient with T2DM between 18 to 65 years with HbA1C 7% - 10%, who can give informed consent. Patient uncontrolled on oral antidiabetics and lifestyle modification for at least 3 months. Patient who are empagliflozin naive. eGFR ˃60 mL/min/1.73m2.
Exclusion Criteria:
Type 1 diabetes, History of recurrent urinary tract infection (UTI), fungal infection, renal and/or hepatic dysfunctions, where RFT and Urine R/E is abnormal, Diabetic Ketoacidosis and/or hyperosmolar hyperglycemic state, severe hypoglycemia, Pregnant or lactating women, Pancreatitis, any serious complications or hypersensitivity.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Empagliflozin naive uncontrolled T2DM on oral anti-diabetics & lifestyle modifications for 3 months
Type 2 diabetic males & females between 18-65 years.
|
Empagliflozin + Metformin (Diampa™-M): 5mg+500mg, 5mg+850mg, 5mg+1000mg, 12.5mg+1000mg, 12.5mg+500mg, 12.5mg+ 850mg Empagliflozin Alone (Diampa™): 10mg, 25mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
SAFETY and TOLERABILITY Outcomes
Time Frame: 6 months
|
Frequency of adverse events, serious adverse events during the course of study follow-up.
Percentage of patients who tolerate empagliflozin.
|
6 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy outcomes
Time Frame: 6 months
|
Change from baseline in HbA1c% and fasting plasma glucose to the last-observation on treatment.
Change from baseline in bodyweight & other study parameters.
|
6 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Ferrannini E, Mark M, Mayoux E. CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis. Diabetes Care. 2016 Jul;39(7):1108-14. doi: 10.2337/dc16-0330.
- Barnett AH, Mithal A, Manassie J, Jones R, Rattunde H, Woerle HJ, Broedl UC; EMPA-REG RENAL trial investigators. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. doi: 10.1016/S2213-8587(13)70208-0. Epub 2014 Jan 24.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GTZ-DM-003-21
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type II Diabetes Mellitus
-
pico-tesla Magnetic Therapies, LLCCompletedType II Diabetes MellitusUnited States
-
KeyBioscience AGEli Lilly and Company; Profil Institut für Stoffwechselforschung GmbH; Nordic...TerminatedType II Diabetes MellitusGermany
-
Medical College of WisconsinMedical University of South CarolinaCompletedDiabetes Mellitus | Type 2 Diabetes Mellitus | Adult-Onset Diabetes Mellitus | Non-Insulin-Dependent Diabetes Mellitus | Noninsulin Dependent Diabetes Mellitus, Type IIUnited States
-
HealthInsightCenter for Technology and Aging; VoxivaUnknownType II Diabetes MellitusUnited States
-
University of PretoriaNestlè Nutrition Institute Africa; South African Sugar AssociationCompletedDiabetes Mellitus, Type II [Non-insulin Dependent Type] [NIDDM Type] UncontrolledSouth Africa
-
University of PrimorskaUniversity of Ljubljana School of Medicine, SloveniaCompletedDiabetes Mellitus Type II,Slovenia
-
Microbio Co LtdCompleted
-
Laboratorios Silanes S.A. de C.V.RecruitingDyslipidemia Associated With Type II Diabetes MellitusMexico
-
EMSRecruitingDyslipidemia Associated With Type II Diabetes MellitusBrazil
Clinical Trials on Empagliflozin
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 1Austria, Germany
-
University Medical Centre LjubljanaUnknownDiabetes Complications | Diabetes Mellitus, Type 1 | Vascular Stiffness | Hypoglycemic AgentsSlovenia
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 1Japan
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, Australia, Canada, Estonia, France, Georgia, Germany, Guatemala, Italy, Latvia, Lithuania, Mexico, New Zealand, Poland, Russian Federation, South Africa, Spain, Ukraine
-
Boehringer IngelheimEli Lilly and CompanyCompletedDiabetes Mellitus, Type 2United States, France, Israel, Mexico, South Africa
-
Boehringer IngelheimEli Lilly and CompanyCompleted
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimEli Lilly and CompanyCompleted
-
Dong-A ST Co., Ltd.CompletedType2 DiabetesKorea, Republic of
-
Collegium Medicum w BydgoszczyRecruitingMetabolic SyndromePoland